Open Access

High expression of interleukin‑enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma

  • Authors:
    • Zhangyan Xu
    • Hua Huang
    • Xing Li
    • Cheng Ji
    • Yifei Liu
    • Xiaojuan Liu
    • Jun Zhu
    • Zhendong Wang
    • Haijian Zhang
    • Jiahai Shi
  • View Affiliations

  • Published online on: January 22, 2020     https://doi.org/10.3892/ol.2020.11330
  • Pages: 2141-2152
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Interleukin‑enhancer binding factor 3 (ILF3) is a double‑stranded RNA‑binding protein that has been reported to contribute to the occurrence and progression of various malignant tumors. The aim of the present study was to evaluate the prognostic value of ILF3 and to apply this knowledge to avoid excessive medical treatment in patients with lung adenocarcinoma (LUAD). ILF3 expression in a discovery set consisting of tumor and peri‑tumor tissue microarrays was analyzed using immunohistochemical methods. The mRNA level of ILF3 was subsequently analyzed in a validation set downloaded from The Cancer Genome Atlas. The Kaplan‑Meier method, univariate and multivariate Cox analyses, decision curve analysis and nomogram models were used to evaluate the prognostic value of ILF3. ILF3 expression was upregulated in tumor tissues compared with peri‑tumor tissues and was negatively associated with the overall survival time of patients with LUAD in the discovery and validation sets. Moreover, ILF3 expression was used for risk stratification in patients with tumor‑node‑metastasis stages II‑IV and poor‑to‑moderate tumor differentiation. ILF3 expression was identified as an independent predictor of adverse prognosis for patients with LUAD in the discovery and validation sets. Finally, nomogram models for the 3‑ and 5 year survival time of patients with LUAD revealed that ILF3 expression may be used to improve the predictive accuracy of the prognosis and to avoid excessive medical treatment for certain patients with the disease. Overall, the data obtained in the current study revealed that high ILF3 expression was associated with poor prognosis, and demonstrated that ILF3, as a potential independent risk factor, may improve the hierarchical postoperative management of patients with LUAD.

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Xu, Z., Huang, H., Li, X., Ji, C., Liu, Y., Liu, X. ... Shi, J. (2020). High expression of interleukin‑enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma. Oncology Letters, 19, 2141-2152. https://doi.org/10.3892/ol.2020.11330
MLA
Xu, Z., Huang, H., Li, X., Ji, C., Liu, Y., Liu, X., Zhu, J., Wang, Z., Zhang, H., Shi, J."High expression of interleukin‑enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma". Oncology Letters 19.3 (2020): 2141-2152.
Chicago
Xu, Z., Huang, H., Li, X., Ji, C., Liu, Y., Liu, X., Zhu, J., Wang, Z., Zhang, H., Shi, J."High expression of interleukin‑enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma". Oncology Letters 19, no. 3 (2020): 2141-2152. https://doi.org/10.3892/ol.2020.11330